Advanced search
Publication Cover
European Clinical Respiratory Journal Volume 7, 2020 - Issue 1
Submit an article Journal homepage
2,706
Views
5
CrossRef citations to date
0
Altmetric
Case Report

Remarkable benefits of intravenous immunoglobulin (IVIG) in a patient with polymyositis-associated acute interstitial lung disease

Soran Peshbahara Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, DenmarkCorrespondence[email protected]
View further author information
&
Elisabeth Bendstrup. Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus N, DenmarkORCID Iconhttps://orcid.org/0000-0002-4238-6963View further author information
ORCID Icon
Article: 1840706 | Received 20 Dec 2019, Accepted 19 Oct 2020, Published online: 26 Oct 2020

References

  • Schmidt J. Current classification and management of inflammatory myopathies. J Neuromuscul Dis. 2018;5(2):109–6.
  • Furst DE, Amato AA, Iorga ŞR, et al. Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve. 2012;45(5):676–683.
  • Schnabel A, Reuter M, Biederer J, et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum. 2003;32(5):273–284.
  • Fathi M, Lundberg IE. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol. 2005;17(6):701–706.
  • Kashiwabara K, Ota K. Rapidly progressive interstitial lung disease in a dermatomyositis patient with high levels of creatine phosphokinase, severe muscle symptoms and positive anti-Jo-1 antibody. Intern Med. 2002;41(7):584–588.
  • Oddis CV. Update on the pharmacological treatment of adult myositis. J Intern Med. 2016;280(1):63–74.
  • Mimori T, Nakashima R, Hosono Y. Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep. 2012;14(3):264–274.
  • Morisset J, Johnson C, Rich E, et al. Management of myositis-related interstitial lung disease. Chest. 2016;150(5):1118–1128.
  • Wallace B, Vummidi D, Khanna D. Management of connective tissue diseases associated interstitial lung disease: a review of the published literature. Curr Opin Rheumatol. 2016;28(3):236–245.
  • Gordon PA, Winer JB, Hoogendijk JE, et al. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev. 2012;8:CD003643.
  • Marie I, Dominique S, Rémy-jardin M, et al. Interstitial lung diseases in polymyositis and dermatomyositis. Rev Med Interne. 2001;22(11):1083–1096.
  • Tubéry M, Lauque D, Murris M, et al. Course of interstitial lung diseases associated with inflammatory myopathies. Apropos of 5 cases. Ann Med Internet (Paris). 1997;148(1):2–10.
  • Tomsic M, Sifrer F. Acute respiratory distress syndrome in a polymyositis patient with the anti-Jo-1 antibody. Wien Klin Wochenschr. 2000;112(15–16):728–731.
  • Quick A, Tandan R. Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease. Curr Rheumatol Rep. 2011;13(3):192–198.
  • Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291(19):2367–2375.
  • Kamali S, Cefle A, Sayarlioglu M, et al. Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases. Rheumatol Int. 2005;25(3):211–214.
  • Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291(19):2367–2375.
  • Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329(27):1993–2000.
  • Miyasaka N, Hara M, Koike T, et al. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol. 2012;22(3):382–393.
  • Saito E, Koike T, Hashimoto H, et al. Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis. Mod Rheumatol. 2008;18(1):34–44.
  • Huapaya JA, Hallowell R, Silhan L, et al. Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease. Respir Med. 2019;154:6–11.
  • Suzuki Y, Hayakawa H, Miwa S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung. 2009;187(3):201–206.
  • Miyazaki E, Ando M, Muramatsu T, et al. Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositis. Clin Rheumatol. 2007;26(3):436–439.
  • Murota H, Muroi E, Yamaoka T, et al. Successful treatment with regimen of intravenous gamma globulin and cyclophosphamide for dermatomyositis accompanied by interstitial pneumonia, opportunistic infection and steroid psychosis. Allergol Int. 2006;55(2):199–202.
  • Diot E, Carmier D, Marquette D, et al. IV immunoglobulin might be considered as a first-line treatment of severe interstitial lung disease associated with polymyositis. Chest. 2011;140(2):562–563.
  • Bakewell CJ, Raghu G. Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. Chest. 2011;139(2):441–443.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.